Vanda Pharmaceuticals (VNDA) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $4.03, -4.95% vs the prior close of $4.24.
- Volume 1.05M shares, 1.1x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
VNDA slides 5.0% to $4.03, a 52-week low. Closed at $4.03, -4.95% vs the prior close of $4.24. Day range $3.99–$4.27, opened at $4.25.
VNDA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — VNDA slides 5.0% to $4.03, a 52-week low
- Closed at $4.03, -4.95% vs the prior close of $4.24. Day range $3.99–$4.27, opened at $4.25.
- Volume was 1.05M shares, 1.1x its 50-day average of 998.12K.
- Price is -19.9% vs its 50-day average ($5.03) and -37.1% vs its 200-day average ($6.41).
- 52-week range $3.99–$9.94; today's close sits at 1% of that range, 59.5% below the 52-week high.
Oct 15, 2026 — VNDA rises 0.5% to $4.24
- Closed at $4.24, +0.47% vs the prior close of $4.22. Day range $4.01–$4.31, opened at $4.04.
- Volume was 1.05M shares, 1.0x its 50-day average of 1.01M.
- Price is -16.1% vs its 50-day average ($5.05) and -34.0% vs its 200-day average ($6.42).
- 52-week range $4.01–$9.94; today's close sits at 4% of that range, 57.3% below the 52-week high.
Oct 14, 2026 — VNDA dips 1.9% to $4.22, a 52-week low, 3 down days in a row
- Closed at $4.22, -1.86% vs the prior close of $4.30. Day range $4.20–$4.39, opened at $4.29.
- Volume was 1.05M shares, 1.1x its 50-day average of 1.00M.
- Price is -16.7% vs its 50-day average ($5.07) and -34.4% vs its 200-day average ($6.44).
- 52-week range $4.20–$9.94; today's close sits at 0% of that range, 57.5% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — VNDA slides 5.3% to $4.30, a 52-week low
- Closed at $4.30, -5.29% vs the prior close of $4.54. Day range $4.28–$4.54, opened at $4.53.
- Volume was 761.30K shares, 0.8x its 50-day average of 1.00M.
- Price is -15.5% vs its 50-day average ($5.09) and -33.3% vs its 200-day average ($6.45).
- 52-week range $4.27–$9.94; today's close sits at 1% of that range, 56.7% below the 52-week high.
Oct 12, 2026 — VNDA dips 0.7% to $4.54
- Closed at $4.54, -0.66% vs the prior close of $4.57. Day range $4.48–$4.56, opened at $4.56.
- Volume was 519.70K shares, 0.5x its 50-day average of 1.00M — lighter than usual.
- Price is -11.1% vs its 50-day average ($5.11) and -29.8% vs its 200-day average ($6.46).
- 52-week range $4.27–$9.94; today's close sits at 5% of that range, 54.3% below the 52-week high.
Oct 9, 2026 — VNDA rises 0.9% to $4.57
- Closed at $4.57, +0.88% vs the prior close of $4.53. Day range $4.47–$4.59, opened at $4.51.
- Volume was 639.90K shares, 0.6x its 50-day average of 1.01M.
- Price is -10.7% vs its 50-day average ($5.12) and -29.4% vs its 200-day average ($6.48).
- 52-week range $4.27–$9.94; today's close sits at 5% of that range, 54.0% below the 52-week high.
Oct 8, 2026 — VNDA dips 0.7% to $4.53
- Closed at $4.53, -0.66% vs the prior close of $4.56. Day range $4.35–$4.54, opened at $4.52.
- Volume was 978.90K shares, 1.0x its 50-day average of 1.01M.
- Price is -11.7% vs its 50-day average ($5.13) and -30.2% vs its 200-day average ($6.49).
- 52-week range $4.27–$9.94; today's close sits at 5% of that range, 54.4% below the 52-week high.
Oct 7, 2026 — VNDA rises 0.9% to $4.56
- Closed at $4.56, +0.88% vs the prior close of $4.52. Day range $4.44–$4.64, opened at $4.48.
- Volume was 757.80K shares, 0.8x its 50-day average of 1.00M.
- Price is -11.3% vs its 50-day average ($5.14) and -29.8% vs its 200-day average ($6.50).
- 52-week range $4.27–$9.94; today's close sits at 5% of that range, 54.1% below the 52-week high.
Oct 6, 2026 — VNDA dips 1.3% to $4.52, a 6-month low on 1.8x normal volume
- Closed at $4.52, -1.31% vs the prior close of $4.58. Day range $4.43–$4.60, opened at $4.60.
- Volume was 1.80M shares, 1.8x its 50-day average of 982.31K — unusually heavy trading.
- Price is -12.3% vs its 50-day average ($5.15) and -30.6% vs its 200-day average ($6.51).
- 52-week range $4.27–$9.94; today's close sits at 4% of that range, 54.5% below the 52-week high.
- That makes 6 straight losses.
Oct 5, 2026 — VNDA dips 1.1% to $4.58, a 6-month low, 5 down days in a row
- Closed at $4.58, -1.08% vs the prior close of $4.63. Day range $4.49–$4.60, opened at $4.59.
- Volume was 724.30K shares, 0.7x its 50-day average of 983.20K.
- Price is -11.4% vs its 50-day average ($5.17) and -29.8% vs its 200-day average ($6.52).
- 52-week range $4.27–$9.94; today's close sits at 5% of that range, 53.9% below the 52-week high.
- That makes 5 straight losses.
Oct 2, 2026 — VNDA slides 3.7% to $4.63, a 6-month low, 4 down days in a row
- Closed at $4.63, -3.74% vs the prior close of $4.81. Day range $4.57–$4.85, opened at $4.85.
- Volume was 1.45M shares, 1.5x its 50-day average of 971.90K.
- Price is -10.6% vs its 50-day average ($5.18) and -29.1% vs its 200-day average ($6.53).
- 52-week range $4.27–$9.94; today's close sits at 6% of that range, 53.4% below the 52-week high.
- That makes 4 straight losses.
VNDA latest news & SEC filings
Every SEC filing by or about VNDA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 9, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 19, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $50.53M (prior year $52.59M) (-3.9% vs Jun 30, 2025)
- Net income: -$62.51M (prior year -$27.21M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$1.04 (prior year -$0.46) (loss widened vs Jun 30, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade VNDA
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 6, 2026, Feb 11, 2026, Oct 29, 2025. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.94% (largest 5.3%).
- Liquidity: about 1.14M shares (≈$4.59M) trade per day on average.
- 52-week position: $4.03 vs a range of $3.99–$9.94 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 24 sales; latest: Joakim Wijkstrom sold 30,800 shares on Mar 2, 2026.
- Latest filings: 10-Q Aug 6, 2026; 8-K Aug 5, 2026; 8-K Jun 5, 2026.
- Share count: 60.46M shares outstanding (Jul 30, 2026), +2.3% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
VNDA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 4.25 | 4.27 | 3.99 | 4.03 | 1.05M |
| Oct 15, 2026 | 4.04 | 4.31 | 4.01 | 4.24 | 1.05M |
| Oct 14, 2026 | 4.29 | 4.39 | 4.20 | 4.22 | 1.05M |
| Oct 13, 2026 | 4.53 | 4.54 | 4.28 | 4.30 | 761.30K |
| Oct 12, 2026 | 4.56 | 4.56 | 4.48 | 4.54 | 519.70K |
| Oct 9, 2026 | 4.51 | 4.59 | 4.47 | 4.57 | 639.90K |
| Oct 8, 2026 | 4.52 | 4.54 | 4.35 | 4.53 | 978.90K |
| Oct 7, 2026 | 4.48 | 4.64 | 4.44 | 4.56 | 757.80K |
| Oct 6, 2026 | 4.60 | 4.60 | 4.43 | 4.52 | 1.80M |
| Oct 5, 2026 | 4.59 | 4.60 | 4.49 | 4.58 | 724.30K |
| Oct 2, 2026 | 4.85 | 4.85 | 4.57 | 4.63 | 1.45M |
| Oct 1, 2026 | 4.90 | 4.96 | 4.79 | 4.81 | 1.35M |
| Sep 30, 2026 | 5.16 | 5.19 | 4.90 | 4.91 | 3.08M |
| Sep 29, 2026 | 5.17 | 5.18 | 5.00 | 5.03 | 2.67M |
| Sep 28, 2026 | 5.05 | 5.17 | 4.97 | 5.17 | 812.90K |
| Sep 25, 2026 | 5.01 | 5.07 | 4.93 | 5.05 | 722.70K |
| Sep 24, 2026 | 5.05 | 5.06 | 4.94 | 4.98 | 913.10K |
| Sep 23, 2026 | 5.32 | 5.33 | 5.00 | 5.04 | 904.80K |
| Sep 22, 2026 | 5.19 | 5.23 | 5.10 | 5.21 | 617.80K |
| Sep 21, 2026 | 5.15 | 5.17 | 5.05 | 5.16 | 938.80K |
About Vanda Pharmaceuticals
Vanda Pharmaceuticals (VNDA) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WASHINGTON, DC. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1347178.
VNDA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Phaedra Chrousos | Director | Jun 8, 2026 |
| Richard W Dugan | Director | Jun 8, 2026 |
| Charles Cliff Duncan | Director | Jun 8, 2026 |
| Tage Honore | Director | Jun 8, 2026 |
| Stephen Ray Mitchell | Director | Jun 8, 2026 |
| Mihael Hristos Polymeropoulos | President and CEO | Mar 4, 2026 |
| Anne Sempowski Ward | Director | Jun 8, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Gunther Birznieks | SVP, Business Development | Mar 4, 2026 |
| Scott Laverne Howell | VP and Chief People Officer | Apr 13, 2026 |
| Daniel Patrick Mcguire | SVP, GC and Secretary | Jun 8, 2026 |
| Kevin Patrick Moran | SVP, CFO & Treasurer | Mar 4, 2026 |
| Christos Vasilios Mihael Polymeropoulos | Senior VP, Medical Director | Apr 13, 2026 |
| Mihael Hristos Polymeropoulos | President and CEO | Mar 4, 2026 |
| Joakim Wijkstrom | SVP, Chief Marketing Officer | Mar 4, 2026 |
| Timothy Williams | SVP & General Counsel | Mar 4, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Mar 2, 2026 | Joakim Wijkstrom | Sale | 30,800 | $8.27 |
| Mar 2, 2026 | Joakim Wijkstrom | Sale | 30,800 | $8.27 |
| Mar 2, 2026 | Joakim Wijkstrom | Sale | 30,800 | $8.27 |
| Mar 2, 2026 | Joakim Wijkstrom | Sale | 30,800 | $8.27 |
| Mar 2, 2026 | Timothy Williams | Sale | 42,434 | $8.27 |
| Mar 2, 2026 | Timothy Williams | Sale | 42,434 | $8.27 |
| Mar 2, 2026 | Timothy Williams | Sale | 42,434 | $8.27 |
| Mar 2, 2026 | Timothy Williams | Sale | 42,434 | $8.27 |
| Mar 2, 2026 | Gunther Birznieks | Sale | 42,431 | $8.27 |
| Mar 2, 2026 | Gunther Birznieks | Sale | 42,431 | $8.27 |
| Mar 2, 2026 | Gunther Birznieks | Sale | 42,431 | $8.27 |
| Mar 2, 2026 | Gunther Birznieks | Sale | 42,431 | $8.27 |
| Mar 2, 2026 | Mihael Hristos Polymeropoulos | Sale | 156,235 | $8.17 |
| Mar 2, 2026 | Mihael Hristos Polymeropoulos | Sale | 156,235 | $8.17 |
| Mar 2, 2026 | Mihael Hristos Polymeropoulos | Sale | 156,235 | $8.17 |
VNDA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $216.10M | $-220.47M | -3.74 | $-109.44M |
| Dec 31, 2024 | $198.77M | $-18.90M | -0.33 | $-15.76M |
| Dec 31, 2023 | $192.64M | $2.51M | 0.04 | $12.80M |
| Dec 31, 2022 | $254.38M | $6.28M | 0.11 | $31.98M |
| Dec 31, 2021 | $268.68M | $33.15M | 0.58 | $64.21M |
Latest balance sheet: total assets $412.47M, total liabilities $192.28M, cash $55.88M (as of Jun 30, 2026).
VNDA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $5.09 |
| May 6, 2026 | 8-K Item 2.02 (results) | $7.44 |
| Feb 11, 2026 | 8-K Item 2.02 (results) | $7.43 |
| Oct 29, 2025 | 8-K Item 2.02 (results) | $5.41 |
| Jul 31, 2025 | 8-K Item 2.02 (results) | $4.26 |
| May 7, 2025 | 8-K Item 2.02 (results) | $4.38 |
| Feb 13, 2025 | 8-K Item 2.02 (results) | $4.70 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $4.89 |
| Jul 31, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
| Feb 7, 2024 | 8-K Item 2.02 (results) | — |
| Nov 8, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on VNDA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.